Possible mechanisms involved in the discrepancy of hepatic and aortic endothelial nitric oxide synthases during the development of cirrhosis in rats

Liver International

Volumn 29, Issue 5, 2009, Pages 692-700

  Mohammadi, Morvarid Shir ^a,b   Thabut, Dominique ^a,c   Cazals Hatem, Dominique ^a   Galbois, Arnaud ^a,b   Rudler, Marika ^a,b   Bonnefont Rousselot, Dominique ^c,d   Moreau, Richard ^a,b   Lebrec, Didier ^a,b   Tazi, Khalid A ^a,b  

^a BEAUJON HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d Laboratoire de Pharmacognosie   (France)

Author keywords

Akt; Cav 1; Cirrhosis; eNOS; HDL; Portalhy pertension; SR BI

Indexed keywords

CAVEOLIN 1; HIGH DENSITY LIPOPROTEIN; NITRIC OXIDE SYNTHASE; PROTEIN KINASE B; SCAVENGER RECEPTOR BI;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM; ENZYME BLOOD LEVEL; ENZYME REGULATION; LIVER; LIVER CIRRHOSIS; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; TISSUE LEVEL;

ANALYSIS OF VARIANCE; ANIMALS; AORTA; BLOTTING, WESTERN; CAVEOLIN 1; IMMUNOHISTOCHEMISTRY; LIPOPROTEINS, HDL; LIVER; LIVER CIRRHOSIS; NITRIC OXIDE SYNTHASE TYPE III; RATS; SCAVENGER RECEPTORS, CLASS B; TIME FACTORS;

EID: 64749089069     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01909.x     Document Type: Article

References (24)

1. Sogni P, Moreau R, Gadano A, Lebrec D. The role of nitric oxide in the hyperdynamic circulatory syndrome associated with portal hypertension. J Hepatol 1995; 23: 218-24.
2. Langer DA, Shah VH. Nitric oxide and portal hypertension: Interface of vasoreactivity and angiogenesis. J Hepatol 2006; 44: 209-16.
3. Wiest P, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enough. Hepatology 2002; 35: 478-91.
4. Tazi KA, Barriere E, Moreau R, et al. Role of shear stress in aortic eNOS upregulation in rats with biliary cirrhosis. Gastroenterology 2002; 122: 1869-77.
5. Tazi KA, Moreau R, Herve P, et al. Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling. Gastroenterology 2005; 129: 303-14.
6. Iwakiri Y, Tsai MH, McCabe TJ, et al. Phosphorylation of eNOS initiates excessive NO production in early phase of portal hypertension. Am J Physiol Heart Circ Physiol 2002; 10: H2084-90.
7. Thabut D, Tazi KA, Bonnefont-Rousselot D, et al. HDL administration attenuates liver proinflammatory response, restores liver eNOS and lowers portal pressure in cirrhotic rats. Hepatology 2007; 46: 1893-906.
8. Minshall RD, Sessa WC, Stan RV, Anderson RGW, Malik A. Caveolin regulation of endothelial function. Am J Physiol Lung Cell Mol Physiol 2003; 285: L1179-83.
9. Shah V, Cao S, Hendrickson H, Yao J, Katusic ZC. Regulation of hepatic eNOS by caveolin and calmodulin after bile duct ligation in rats. Am J Physiol Gastrointest Liver Physiol 2001; 280: 1209-16.
10. Shaul PW. Regulation of endothelial nitric oxide synthase: Location, location, location. Annu Rev Physiol 2002; 64: 749-74.
11. Liu S, Premont RT, Kontos CD, Zhu S, Rockey DC. A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med 2005; 11: 952-8.
12. Boo YC, Ho H. Flow-dependent regulation of endothelial nitric oxide synthase: Role of protein kinases. Am J Physiol Cell Physiol 2003; 285: C499-508.
13. Matveev S, Uittenbogaard A, van Der Westhuyzen D, Smart EJ. Caveolin-1 negatively regulates SR-BI mediated selective uptake of high-density lipoprotein-derived cholesteryl ester. Eur J Biochem 2001; 268: 5609-16.
14. Camps J, Simo JM, Guaita S, Ferre N, Joven J. Altered composition of lipoproteins in liver cirrhosis compromises three homogeneous methods for HDL-cholesterol. Clin Chem 1999; 45: 685-8.
15. Giron-Gonzalez JA, Martinez-Sierra C, Rodriguez-Ramos C, et al. Implication of inflammation-related cytokines in the natural history of liver cirrhosis. Liver Int 2004; 24: 437-45.
16. Wong F, Bernardi M, Balk R, et al. Sepsis in cirrhosis: Report on the 7th meeting of the International Ascites Club. Gut 2005; 54: 718-25.
17. Lebrec D. Animal models in portal hypertension. In: Okuda K, Benhamou JP, eds. Portal Hypertension: Clinical and Physiological Aspects. Tokyo: Springer-Verlag, 1991; 101-13.
18. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1997; 20: 470-5.
19. Leglise D. Commission de standardisation de l'ARCOL Recommandations pratiques pour le dosage du HDL-C après précipitation par le phosphotungstate de sodium et le chlorure de magnésium. Inf Sci Biol 1996; 13: 2-6.
20. Pinzani M. Non invasive evaluation of hepatic fibrosis. Gut 2006; 55: 310-2.
21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Ann Biochem 1976; 72: 248-54.
22. Frossard JL, Schiffer E, Cikirikcioglu B, et al. Opposite regulation of endothelial NO synthase by HSP90 and caveolin in liver and lungs of rats with hepatopulmonary syndrome. Am J Gastrointest Liver Physiol 2007; 293: G864-70.
23. Morales-Ruiz M, Cejudo-Martin P, Fernandez-Varo G, et al. Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology 2003; 125: 522-31.
24. Habib A, Mihas AA, Abou-Assi SG, et al. High-density lipoprotein cholesterol as an indicator of liver function and prognosis in noncholestatic cirrhotics. Clin Gastroenterol Hepatol 2000; 3: 286-91.